In preclinical studies, ZW25 showed promising activity in HER2-positive cancer cells lines and in breast, gastric, and ovarian CDX (Cell line-Derived Xenograft) and PDX (Patient-Derived Xenografts) models [42]. This evidence concerns the gene ERBB2 and cancer.